GW Pharma Epilepsy Drug Epidiolex Clinical Trial Shows Substantial Reduction in Seizures

New Cannabis Ventures
By NCV NewswireNov 26, 2018, 7:27 am440 pts
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared to placebo – – Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in…

Read Article Share
Share Article
- email
- x.com
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Canada’s cannabis legalization initiative: Funding, outcomes, and departmental spending 77

Florida GOP Lawmaker Files Bill To Ban Public Marijuana Smoking As Campaign Works To Put Legalization On 2026 Ballot 77

Hemp Needs What Alcohol Already Has: A Clear Definition (Op-Ed) 66

Federal Spending Bill Includes Provisions to Prohibit Hemp-Derived THC Products 64

Senate Advances Hemp Product Ban—But GOP Senator Has Last-Ditch Plan To Fight Back 62

Florida Proposal Would Align Cannabis and Tobacco Public Smoking Rules 52

Missouri Officials Propose Tightening Cannabis Licensing Rules 29

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.